Project introduction and objectives

Due to the aging population, cancer is emerging as a major global burden. Indeed, cancer is now the number one cause of death in the Netherlands, with 100,000 new cases diagnosed and more than 40,000 deaths annually. Current drug treatment of metastatic cancer is ineffective: only one in four patients derives benefit from anti-cancer drugs. The last two to three decades has taught us that cancer results from multiple genetic defects and that such defects are often dissimilar in individuals suffering from the same type of cancer. While this explains the heterogeneous response to anti-cancer agents of patients suffering from apparently similar cancers, it provides at the same time a huge obstacle for the effective treatment of cancer.

In recent years, treatment of cancer has been shifting from a “one size fits all” approach to a more personalized approach, in which the patient is treated according to the specific defects present in the individual tumor. This transition is enabled by two major developments: first, the ability to rapidly sequence the DNA of cancers at low cost, which is starting to generate inventories of genetic defects in individual cancers; and second, the development of highly selective cancer therapeutics, which act on the products of the genes that are mutated in cancer. These 'magic bullets' provide targeted treatment options for patients with a defined genotype. However, despite this progress, intrinsic heterogeneity of the tumor and tumor plasticity frequently and rapidly results in resistance to the applied drugs.

The mission of the consortium is to determine and understand genetic alterations in individual tumors in order to deliver precision medicine to individual cancer patients.

Our ambition is to significantly improve life expectancy and quality of life for cancer patients and to provide multidisciplinary training for the next generation of cancer researchers and specialists. brings together prominent cancer research groups from seven research institutions in the Netherlands. The scientists were selected on the basis of their excellence and their commitment to the mission of the program. A number of participants have been long-standing collaborators, in particular through the Cancer Genomics Center (CGC) that was supported by the Netherlands Genomics Initiative (NGI) from 2002 until 2012.

In the program, we combine the expertise, knowledge and infrastructure of internationally established as well as junior basic scientists and clinicians from seven research institutions in the Netherlands to

1) understand how specific genetic changes in individual tumors determine tumor behavior, including their responses to cancer drugs, and

2) bring this new knowledge into the clinic.


12 Jan 2018

annual CGC meeting 2018

All researchers are welcome, however registration is required.

28 Nov 2017

ERC grant for Michiel Vermeulen

Michiel Vermeulen, one of our CGC group leaders, was awarded a prestigious ERC-Consolidator Grant.

Read more >

17 Nov 2017

Fumagalli wins CGC poster prize

Arianna Fumagalli received the 2017 poster award during the CGC meeting New Horizons in Cancer Research

Read more >

More News >


10 & 11 Jan 2019

CGC-Oncode annual scientific meeting

Annual meeting for the CGC and Oncode scientific community

08 & 09 Nov 2018

CGC-Oncode annual conference

Oncode and the Cancer Genomics Centre are pleased to host our annual joint scientific meeting at the KIT Royal Tropical Institute in Amsterdam. This year's topic is “From tissues to cells to molecules: multi-scale visualization of cancer processes”. More information will follow in due course

09 - 13 Jul 2018

Eurolife Summer School 2018

The Eurolife Summer School 2018 is entitled Molecular Mechanisms in Cancer – Translating Discoveries into Personalised Therapies. 

Read more >

More Events >